{
  "docId": "019de073-a711-71bb-a4fc-67d28d18b8d8",
  "docSlug": "26ea3d305f04fe3e604b448e70b259ea",
  "documentTitle": "BenevolentAI | Investor Presentation Deck | 46 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 46,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "Includes explicit caveats regarding the small sample size and short duration of the Phase Ib study.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-a711-71bb-a4fc-67d28d18b8d8/20",
  "deckHref": "/decks/019de073-a711-71bb-a4fc-67d28d18b8d8",
  "deckJsonHref": "/decks/019de073-a711-71bb-a4fc-67d28d18b8d8.json",
  "deckAnchorHref": "/decks/019de073-a711-71bb-a4fc-67d28d18b8d8#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.7,
        "x": 0.15,
        "y": 0.33
      },
      "kind": "chart",
      "text": "Mean Change from Baseline %BSA affected in treated areas",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "69f63562-7542-4e6c-8701-3fb527d75d2a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.15,
        "y": 0.7
      },
      "kind": "legend",
      "text": "Cohort 3: Patients dosed 1% ointment, 30% BSA, once per day; Cohort 4: Patients dosed 1% ointment, 30% BSA, twice per day",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10b22f8f-0885-4fc7-8f58-43ac0a93104c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "Caveats: Phase Ib was NOT powered to meaningfully assess efficacy - only 6 patients dosed with active per group; Maximum duration of dosing 14 days (EASI score changes typically measured at 28 days)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f3b9010-14da-4012-9fb2-27f0caee87d2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.05,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "Eczema Area and Severity Index (EASI)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f853d407-e269-49e9-9533-c5511e4068df",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.05,
        "y": 0.07
      },
      "kind": "title",
      "text": "BEN-2293 - indicative data from Phase Ib",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "655f67b0-3b52-40ea-b16a-20ecc326d872",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}